Oruka Therapeutics, Inc.
ORKA
Classifica tra le azioni
#3262
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Prezzo delle azioni
$81.14
Capitalizzazione di mercato
$5.37B
Variazione (1 giorno)
1.53%
Variazione (1 anno)
204.47%
Paese
US
Scambia Oruka Therapeutics, Inc. (ORKA)
Categoria
Healthcare
Rapporto P/B per Oruka Therapeutics, Inc. (ORKA)
Rapporto P/B al October 2026 TTM: 4.58
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Oruka Therapeutics, Inc., il rapporto P/B attuale (TTM) è 4.58. Alla fine del 2024, era pari a 0.85.
Storico del rapporto P/B per Oruka Therapeutics, Inc. da 2005 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 4.58 | 56.18% |
| 2025 | 2.93 | 243.97% |
| 2024 | 0.85 | -89.28% |
| 2023 | 7.94 | -19.22% |
| 2022 | 9.83 | 39.93% |
| 2021 | 7.03 | 44.25% |
| 2020 | 4.87 | 391.44% |
| 2019 | 0.99 | 30.86% |
| 2018 | 0.76 | -44.72% |
| 2017 | 1.37 | 17.70% |
| 2016 | 1.16 | 51.58% |
| 2015 | 0.77 | -41.86% |
| 2014 | 1.32 | 42.00% |
| 2013 | 0.93 | -46.63% |
| 2012 | 1.74 | -0.42% |
| 2011 | 1.75 | -56.04% |
| 2010 | 3.98 | 27.67% |
| 2009 | 3.12 | -7,157.47% |
| 2008 | -0.04 | -103.06% |
| 2007 | 1.44 | -51.05% |
| 2006 | 2.95 | -50.04% |
| 2005 | 5.90 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| 6.6964 | 46.34% |
US
|
|
| 13.6307 | 197.87% |
US
|
|
| 4.4521 | -2.71% |
AU
|
|
| 4.2241 | -7.69% |
BE
|
|
| 6.3632 | 39.06% |
NL
|
